$7.2B GW Pharma acquisition is another sign of cannabis normalization

This week Jazz Pharmaceuticals said it would acquire GW Pharmaceuticals in a $7.2B cash and stock deal, the strongest indication yet of big drugmakers’ long-speculated interest in cannabis. 

In 2018, the U.S. Food and Drug Administration (FDA) approved GW’s Epidiolex, a CBD-based pharmaceutical, as a treatment for severe pediatric epilepsy disorders. It was the first time the agency greenlit a cannabis-derived drug. 

U.K.-based GW has also developed a medicine containing CBD and THC which . . .